• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1267568 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type% P3 w4 A) t/ P/ }. }4 P$ w
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
/ W  i+ d+ A8 Y- C6 \* Z+ Author Affiliations
- V: C, P' U5 T; B+ m8 T/ ^1 O( k1 s$ Y5 _) y7 y: o
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan * e" |8 P, l( h) ?
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
* W* B$ N& T4 d, S* B3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 3 Z  {8 D7 ]0 {5 p( V0 V$ ^- ^
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
7 Y6 |: s7 `: j+ B9 t5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
: H. _0 m$ h: T/ I0 w& P6 K& d6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
$ W+ I8 q- a' A+ c5 G7Kinki University School of Medicine, Osaka 589-8511, Japan
. M$ N5 X! ^; n$ h; k9 X8Izumi Municipal Hospital, Osaka 594-0071, Japan . _* N3 b. p: y
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan ' g. V* r) y: d9 \" b
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 4 U# N8 ?  y& Y
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 4 [# ~9 J; ?2 a( O% v- U- k% X' H

$ x! f7 J$ p9 K9 G6 T
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type ' D  u- C' k/ l* j7 W& Z# a! Z  X3 i

0 w6 N+ |7 b2 y3 FAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato ( Z$ ^2 R9 V4 A1 e) c) @
# I& Q3 w/ o6 D2 v7 d
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  % Z, d5 |& B" [3 |( w0 E
' Y) D7 t8 B5 g1 T; H
Published online on: Thursday, December 1, 2011 9 ?" X0 v3 p& i; R4 b3 A

9 ~" X) e3 Q0 h  p- B) MDoi: 10.3892/ol.2011.507
5 n6 r1 n& Q. R( ~# \7 T  D) {
! c9 G. e) m" J3 sPages: 405-410
/ K3 u1 j7 ?' m+ X% ]* x1 ^9 z9 M8 r4 ~$ J/ t
Abstract:+ R  Q+ D7 u/ r$ r3 K
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
6 K' c* E7 b4 ~( |
1 j1 h) @3 K. a3 X+ S  S8 T
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
8 I! x9 [% f8 n2 S+ b* K& F$ aF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
: v3 [/ l" ^# g- Y+ Author Affiliations
0 z- m7 K4 ]' H7 n# T  X1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu : A* Z* P4 J' |. y! j2 J. ^
2Department of Thoracic Surgery, Kyoto University, Kyoto
6 ~& m0 |2 \' c. \" h) a3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan : n: a7 i7 p( j3 k1 C: }" `8 h9 m$ M
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
8 O, w% Z8 L4 BReceived September 3, 2010. " P) L* v9 X* t% M( q' g
Revision received November 11, 2010.   i/ f$ ]6 h: l/ Z) M! S
Accepted November 17, 2010.
  }- @/ W) X: D- T* mAbstract1 p2 C* k9 q7 S, k& [" g" x; U: q
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
+ h$ A4 N- [6 ]( a3 d0 @& `Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
' P# N" w& k. v4 N* D+ DResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
5 d' P3 k9 q$ @; S9 D& g' RConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
7 y5 z+ \9 E- E0 z) m1 @7 }
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
) l, z% }0 Q: |* X今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?/ r  @3 ]1 [/ o7 x% ~7 }$ v4 s: t: O
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
/ R% s6 g. I6 \+ C8 g6 zhttp://clinicaltrials.gov/ct2/show/NCT01523587$ ^% I# j2 Y. ~" }% t: R

: m/ Y( u. a* g# [BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
! v& @$ G$ T: |http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 $ X, V5 C5 X9 W: s' `+ U, H; u

1 X' f% d. b! {) F从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。, G: G0 k. {1 ]' q. b2 l
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53
$ T0 V6 \* l3 S$ D& M2 I0 C9 Y从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
6 D* b# x+ `* b( j: ?至今为止,未出 ...
4 B; k$ j! P  O$ }+ R7 _- z9 Z
没有副作用是第一追求,效果显著是第二追求。
5 T4 I' K( [6 M" h不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表